Sugi Predict
/ Targets
/ SETD1B
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to SETD1B by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas |
PHASE1/PHASE2 | UNKNOWN |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation |
PHASE1/PHASE2 | RECRUITING |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis |
PHASE1/PHASE2 | RECRUITING |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer |
PHASE2 | COMPLETED |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome |
PHASE1 | COMPLETED |
| Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load |
PHASE1 | COMPLETED |
| A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) |
PHASE1 | COMPLETED |
| The Efficacy of Allo-HSCT in ND HR-CBF-AML |
nan | RECRUITING |
| PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia |
nan | UNKNOWN |
| Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System |
nan | UNKNOWN |
| Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy |
nan | NOT_YET_RECRUITING |
| The Molecular Pathogenesis Study of Cataract |
nan | UNKNOWN |
| An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF) |
nan | NO_LONGER_AVAILABLE |
| Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia |
nan | COMPLETED |
| Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients |
nan | RECRUITING |
| The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer |
nan | UNKNOWN |
| Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders |
nan | COMPLETED |
| Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity |
nan | UNKNOWN |
| Target of Suv420h1/2 in Hepatocytes |
nan | RECRUITING |
| Mechanisms of Immune Deficiency |
nan | UNKNOWN |
| Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. |
nan | UNKNOWN |
| Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies |
nan | WITHDRAWN |
| CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
nan | UNKNOWN |
| Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients |
nan | COMPLETED |
| Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors |
nan | RECRUITING |
| SRSF2 Gene Mutation in Patients With t-MDS/AML |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a SETD1B binder may also engage these)